Human glioma and prostate cancer cells lost their sensitivity to TRAIL by overexpressing Bcl-2 (Rieger et al, 1998; Munshi et al, 2001; Rokhlin et al, 2001). This evidence concerns the gene BCL2 and central nervous system cancer.